137. Implementing a Community Needs Assessment for Naloxone Vending Machines with Leaders with Lived Experience

Speaker: Jordan Akerley, End Hep C SF, United States & Joanne Kay, End Hep C SF, United States

---

140. Gender differences in HIV and viral hepatitis prevalence, associated risk behaviors, and intimate partner violence among women who inject drugs in Kenya

Speaker: Matthew Akiyama, Albert Einstein College of Medicine, United States

---

139. High rates HCV, HIV, and associated risk behaviors among criminal legal system involved people who inject drugs in Kenya

Speaker: Matthew Akiyama, Albert Einstein College of Medicine, United States

---

138. Viral hepatitis and HIV risk among older vs younger people who inject drugs in Kenya

Speaker: Matthew Akiyama, Albert Einstein College of Medicine, United States

---

141. Cost of Hepatitis C Virus self-testing in Malaysia: A micro-costing study

Speaker: Asra Asgharzadeh, Bristol University, United Kingdom

---

142. Retrospective Chart Review for Hepatitis C Treatment for People Who Use Drugs in Victoria, British Columbia

Speaker: Tamara Barnett, Cool Aid Community Health Center, Canada

---

143. The role of whole genome sequencing in revealing an HCV outbreak in Northern Ireland.

Speaker: Daniel Bradshaw, UK Health Security Agency, United Kingdom

---

145. Current prevalence of and risk factors for liver cirrhosis in opioid agonist therapy patients of the SAMMSU cohort after 5 years of unrestricted DAA access.

Speaker: Andrea Bregenzer, Abbvie Ag, Switzerland

---

144. Occurrence and outcome of hepatitis C reinfections in opioid agonist therapy patients of the SAMMSU cohort.

Speaker: Andrea Bregenzer, Abbvie Ag, Switzerland

---

146. The evaluation of people suspected of sexually transmitted diseases requires tools for the comprehensive diagnosis of viral hepatitis and HIV.

Speaker: Joaquin Cabezas, University Hospital Marques De Valdecilla, Spain

---

147. Disrupting generational trauma through advocacy, support, and connection.

Speaker: Sarah Campbell, Horizon Health Network, Canada

---

148. Supporting Birthing People Who Use Substances by Facilitating Connection to Health and Community Services

Speaker: Sarah Campbell, Horizon Health Network, Canada

---

149. Acceptability of long-acting injectable antiretroviral therapy among people living with HIV who use drugs and service providers

Speaker: Alexandra Collins, Brown University School Of Public Health, United States

---

150. Laws restricting access to opioid treatment programs – a typology in the United States

Speaker: Anna Conway, Kirby Institute, Unsw, Australia

---

151. Data and Evidence to Drive Hepatitis B and C Service Scale-up

Speaker: Colleen Daniels, Harm Reduction International, United Kingdom

---

152. Sex work or male-with-male sexual activity and the risks of HCV and HIV acquisition among people who inject drugs: a systematic review and meta-analysis

Speaker: Joshua Dawe, University of Bristol, United Kingdom

---

153. Rapid hepatitis C treatment initiation among people who inject drugs in Armenia, Georgia, and Tanzania: trial protocol

Speaker: Bridget Draper, Burnet Institute, Australia

---

154. Wholistic conversations on the liver and hepatitis C: A visual Indigenous wellness perspective.

Speaker: Kate Dunn, University Of Toronto, Canada

---

157. Awareness of Hepatitis C Infection Among People Who Inject Drugs, England, Wales, and Northern Ireland

Speaker: Helen Dwyer, UKHSA, United Kingdom

---

156. High risk of hepatitis C seroconversion amongst females with exposure to both prison and drug treatment in England.

Speaker: Helen Dwyer, UKHSA, United Kingdom

---

155. Testing and vaccination uptake among people who inject drugs with a history of incarceration, England, Wales, and Northern Ireland.

Speaker: Helen Dwyer, UKHSA, United Kingdom

---

158. Poly-Drug Use And Unsafe Sexual Health Seeking Behaviour Amongst Young Women Who Inject Drugs Living With Viral Hepatitis : A Case Study Across Five (5) High Risk Local Government Areas In Lagos, Nigeria.

Speaker: James Eghaghe, Equal Health and Rights Access Advocacy Initiative -EHRAAI, Nigeria

---

159. Survival of PWID with and without HCV – a long-term, population-based study from Iceland, 2000-2022.

Speaker: Thorgerdur Einarsdottir, University Of Iceland, Iceland

---

160. Hepatitis C, Incarceration, and Drug Use: A Case for Resourcing Jail-Based HCV Treatment in the United States

Speaker: Shelley Facente, Facente Consulting, United States

---

161. The epidemiology of substance use and disorders in Nigeria: A threat to achieving the goal of reducing the level of hepatitis infections.

Speaker: Chia Francis, ,

---

173. Comparison of risk and protective factors in birthing people who use substances (BPWUS) with and without a history of conviction who have used substances during pregnancy.

Speaker: Sarah Gander, NB Social Pediatrics, Canada

---

174. Hepatitis C (HCV) treatment history among people who inject drugs (PWID) in Georgia – Integrated Bio-Behavioral Surveillance Survey (IBSS), 2022.

Speaker: Lasha Gulbiani, Health Research Union, Georgia

---

109. Incidence rate of hepatitis C virus infection in the prison setting: The STOP-C study.

Speaker: Andrew Lloyd, Unsw / Kirby Institute, Australia

---

175. Whose needs are getting met? The experiences of people in the United Kingdom who inject illicit drugs who remain hepatitis C positive after a course of treatment which was not taken as prescribed.

Speaker: Louise Hansford, Hep C U Later (Inclusion MPFT), UK

---

176. Exploring opportunities and missed opportunities for hepatitis C treatment uptake among people who inject drugs in Australia: A qualitative study.

Speaker: Margaret Hellard, Burnet Institute, Australia

---

225. Life chaos, social support, and subsequent emergency department use among people who inject drugs in Québec, Canada

Speaker: Stine Bordier Høj, Centre hospitalier de l’Université de Montréal, Canada

---

166. Use of expert knowledge elicitation methods for monitoring purposes: the PEOPLE project.

Speaker: Blanca Iciar Indave Ruiz, EMCDDA, Portugal

---

19. Community-based HCV treatment model for PWIDs in Ukraine’s war emergency.

Speaker: Zahedul ISLAM, Alliance for Public Health, Ukraine

---

167. Effect of pre-exposure prophylaxis on the prevention of HIV/AIDS in the city of Douala.

Speaker: NKOMBOU TCHAPON JAURES JIMYTRY, Alcondoms Cameroun, Cameroon

---

169. Experiences with fentanyl and tranquilizer use, overdose, and harm reduction behaviors in participants from a Philadelphia, PA (USA) harm reduction organization.

Speaker: Amy Jessop, HepTREC at Prevention Point Philadelphia, United States

---

171. HBV Actions in US Harm Reduction Organizations: Perspectives from the Field

Speaker: Amy Jessop, HepTREC at Prevention Point Philadelphia, United States

---

168. Polydrug use pattern among harm reduction program participants: Implications for prevention and care services.

Speaker: Amy Jessop, HepTREC at Prevention Point Philadelphia, United States

---

170. Wound-related Perceptions and Care Among Participants from a Philadelphia, PA (USA) Harm Reduction Organization

Speaker: Amy Jessop, HepTREC at Prevention Point Philadelphia, United States

---

172. The impact of severe mental illness on treatment retention and all-cause mortality of people in opioid agonist treatment: A retrospective data linkage study in New South Wales.

Speaker: Nicola Jones, National Drug And Alcohol Research Centre, Australia

---

177. Integrating Harm Reduction Services into a State-Wide Substance Use Disorder System of Care

Speaker: Ashly Jordan, New York State Office of Addiction Services and Supports, United States

---

178. Population size estimation of people who inject drugs in Georgia.

Speaker: George Kamkamidze, Clinic Neolab, Georgia

---

179. Practice of sharing injection devices among different age groups of people who inject drugs in Georgia (Integrated Bio-Behavioral Surveillance Survey 2022).

Speaker: Giorgi Kanchelashvili, Health Research Union, Georgia

---

182. Age differences and geographical variations in illicit drug-related mortality in Iran: A Bayesian spatial analysis

Speaker: Mohammad Karamouzian, Centre On Drug Policy Evaluation, St. Michael’s Hospital, Canada

---

180. Characterizing opioid agonist therapy uptake among people who inject drugs in Iran: Results from a national bio-behavioral surveillance survey in 2020.

Speaker: Mohammad Karamouzian, Centre On Drug Policy Evaluation, St. Michael’s Hospital, Canada

---

181. Short-term social and substance use-related outcomes among clients of safer opioid supply programs in Toronto, Canada

Speaker: Mohammad Karamouzian, Centre On Drug Policy Evaluation, St. Michael’s Hospital, Canada

---

189. Changes in behaviors among people who inject drugs in San Diego, California during the SARS-CoV-2 pandemic

Speaker: Jordan Killion, University Of California, San Diego, United States

---

190. Use of preventive and treatment programs by injecting drug users in Georgia (data from Integrated Bio-Behavioral Survey, 2022).

Speaker: Marika Kochlamazashvili, Health Research Union, Georgia

---

191. Gender differences in hepatitis C exposure and care cascade among people who inject drugs

Speaker: Sarah Larney, Université De Montréal, Canada

---

42. Measuring hepatitis C and HIV incidence in people who inject drugs during the COVID-19 pandemic

Speaker: Sarah Larney, Université De Montréal, Canada

---

192. Pre-natal Hepatitis C (HCV) Screening and Post-Natal Linkage to Care at CUPS, an Inner-City Clinic for People Experiencing Vulnerability in Canada

Speaker: Gisela Macphail, CUPS Liver Clinic, Canada

---

194. Overdose prevention centers in the United States: A multi-level evaluation.

Speaker: Brandon Marshall, Brown University School Of Public Health, United States

---

193. Transforming data for harm reduction progress: Lessons on predictive analytics from the US-based PROVIDENT project

Speaker: Brandon Marshall, Brown University School Of Public Health, United States

---

196. Chronicles of an Epidemic Forthtold: Alarming increase of HCV and HIV among People Who Inject Drugs in Colombia

Speaker: Pedro Mateu-Gelabert, CUNY – School Of Public Health, United States

---

195. Hepatitis c virus care cascade among people who inject drugs in Puerto Rico: Minimal HCV treatment and substantial barriers to HCV care

Speaker: Pedro Mateu-Gelabert, CUNY – School Of Public Health, United States

---

197. The role of access to psychosocial support services at opioid agonist treatment sites in reaching the 95-95-95 HIV cascade in people who inject drugs in Ukraine: Country-level data.

Speaker: Anna Meteliuk, Alliance For Public Health, Украина

---

198. Methodology to investigate trends in hepatitis C virus reinfection among people who inject drugs in England.

Speaker: Holly Mitchell, UK Health Security Agency, United Kingdom

---

200. Hepatitis C cascade of care in individuals tested in drug services after the introduction of direct-acting antivirals, 2016-2022.

Speaker: Amber Newbigging-lister, Senior surveillance and prevention scientist, United Kingdom

---

199. Understanding loss to follow up for HCV treatment in England among people who inject drugs who are chronically infected with HCV, using data from the national treatment register 2018-2021

Speaker: Amber Newbigging-lister, Senior surveillance and prevention scientist, United Kingdom

---

201. Reduction of Health and socio-economic risks, fight against hepatitis B and C and human right among drug users in Burundi

Speaker: JEANNE D’ARC NIYOMWUNGERE, Association Burundaise Pour Un Monde De Paix Sans Drogues /abmpd, Burundi

---

17. Racial/ethnic differences in receipt of naloxone distributed by opioid overdose prevention programs in New York City.

Speaker: Shayla Nolen, Brown University School Of Public Health, United States

---

202. Hepatitis C Virus among Patients Visiting a Sexually Transmitted Infections Clinic

Speaker: Amy Nunn, Rhode Island Public Health Institute, Brown University, United States

---

204. Micro-elimination in Cairns by 2030: A modelling study to demonstrate the impact of Cairns Hep C Free Program.

Speaker: Alisa Pedrana, Burnet Institute, Australia

---

203. Preparing for the final phase of elimination: A test-and-treat approach to micro-elimination of hepatitis C in Cairns, Australia.

Speaker: Alisa Pedrana, Burnet Institute, Australia

---

205. Characteristics and service needs of a community-based sample of people who use drugs in Amadora (Lisbon).

Speaker: Joana Pires, NOVA National School Of Public Health, Universidade Nova De Lisboa, Portugal

---

206. Skin infections in people who use drugs: Learnings from a mixed-methods survey in Wales, 2023

Speaker: Amy Plimmer, Public Health Wales, United Kingdom

---

207. Sexual behavior and sexually transmitted infections among people who inject drugs: A systematic review.

Speaker: Olivia Price, National Drug And Alcohol Research Centre, Australia

---

18. Hepatitis C (HCV) reinfection and risk factors among people who inject drugs (PWID) and other priority populations of the Kirketon Road Centre, an integrated primary healthcare service in Kings Cross, Sydney

Speaker: Phillip Read, Kirketon Road Centre, Australia

---

184. Mortality Trends in People Who Inject Drugs and Other People Living with HIV and HCV in the DAA-era: An International Comparison (InCHEHC, 2010-2019).

Speaker: Maria-Bernarda Requena, Iplesp, France

---

208. High Rates of Recent Substance Use Among Transgender People with HIV Associated with Riskier Sexual Behavior

Speaker: Elana Rosenthal, Institute of Human Virology, University of Maryland School of Medicine, United States

---

188. Prevalence of Comorbid Substance Use Disorders among People with Opioid Use Disorder: A Systematic Review & Meta-Analysis

Speaker: Thomas Santo Jr, NDARC, UNSW Sydney, Australia

---

210. Dynamics of Psychological Distress in People Who Inject Drugs by Hepatitis C Virus Infection Status: Preliminary Results from an Exploratory Analysis of the HEPCO Study, Montreal, Canada.

Speaker: Heidar Sharafi, Research Centre, Centre Hospitalier de l’Université de Montréal (CRCHUM), Canada

---

211. Screening for human trafficking and concomitant substance use in the emergency department: Missed opportunities for enhanced interdisciplinary collaboration.

Speaker: Sanjeev Sirpal, Vitalite Health Network, University Of Montreal, Canada

---

39. Outbreak of HIV Among People Who Inject Drugs (PWID) Discovered Through Phylogenetic Analysis: Are We Seeing Just the Top of the Iceberg?

Speaker: Alessandro Soria, Fondazione IRCCS San Gerardo Dei Tintori, Italy

---

213. Challenges on the road to HCV elimination: Identifying gaps in HCV testing and treatment among people who inject drugs in England.

Speaker: Jack Stone, University Of Bristol, United Kingdom

---

212. Imprisonment among people who use methamphetamine: Preliminary results from a prospective cohort study.

Speaker: Jack Stone, University Of Bristol, United Kingdom

---

40. Modelling the contribution of incarceration, HIV and drug injection to TB transmission among people who inject drugs in Ukraine

Speaker: Jack Stone, University Of Bristol, United Kingdom

---

214. A prison-tailored monitoring and evaluation framework for viral hepatitis B and C in the EU

Speaker: Lara Tavoschi, University of Pisa, Italia

---

215. Access to Opioid Substitution Therapy for the Incarcerated People Who Use Drugs in Kiambu County, Kenya.

Speaker: Angela Thiongo, Medecins Sans Frontieres (MSF), Kenya

---

216. Prévalence du VIH, Hépatite B et C chez les consommateurs de drogues injectables en Côte d’Ivoire : Défis de santé publique

Speaker: Félicien Yomi TIA, PROGRAMME NATIONAL DE LUTTE CONTRE LE TABAGISME, L’ALCOOLISME, LA TOXICOMANIE ET LES AUTRES ADDICTIO, Côte d’Ivoire

---

217. Hepatitis C virus treatment uptake among people with recent incarceration in New South Wales, Australia: a population-based linkage study

Speaker: Shane Tillakeratne, The Kirby Institute, Unsw, Australia

---

218. Chronic pain and opioid agonist therapy among people who inject drugs: Is there potential for better pain treatment outcomes?

Speaker: Sasha Udhesister, Université De Montréal, Canada

---

219. Prevalence of Hepatitis C among People Who Inject Drugs in New York State

Speaker: Tomoko Udo, University At Albany, School Of Public Health, United States

---

223. Gender differences in the association between sex work and housing status among people who inject drugs in Montreal, Canada.

Speaker: Farzaneh Vakili, Université de Montréal, Canada

---

187. Gender-related differences in treatment for hepatitis C virus between men and women who inject drugs: The ETHOS ENGAGE study.

Speaker: Heather Valerio, The Kirby Institute, Australia

---

220. Assessing Hepatitis C testing and treatment uptake among PWID in Georgia

Speaker: Annette Verster, WHO, Switzerland

---

221. Naloxone possession and carriage among people who use opioids in NYC: The impact of person-level and time-varying contextual factors

Speaker: Kathleen Ward, Drexel University, United States

---

224. Willingness to use harm reduction vending machine kiosks among people who inject drugs in rural Appalachia.

Speaker: April Young, University Of Kentucky, US

---

183. A Comparison of Sofosbuvir/Velpatasvir (S/V) and Glecaprevir/Pibrentasvir (G/P) for the Treatment of HCV Infection Among HCV-Infected People Who Use Drugs (PWUD)

Speaker: Rossitta Yung, Vancouver Infectious Diseases Centre, Canada

---

222. International harm reduction indicators are still not reached: Results from the second round of a cross-sectional study on drug paraphernalia distribution in Germany, 2021.

Speaker: Ruth Zimmermann, Robert Koch Institut, Germany

---

162. Increasing HCV screening rates by integrating the PATHOntario Hepatitis C (HCV) virtual self-screening model of care with opioid agonist therapy (OAT) services at TrueNorth Medical Treatment Centre clinics.

Speaker: Liza Abraham, PATHOntario, Canada

---

23. Integrating a novel virtual model of care for the screening and treatment of hepatitis C for clients enrolled in an opioid agonist management (OAT) program.

Speaker: Liza Abraham, PATHOntario, Canada

---

77. “It’s really refreshing to be involved in something where our perspective and opinion was respected and taken seriously” – Co-designing It’s Your Right, a peer-led hepatitis C health promotion campaign for people who inject drugs.

Speaker: Alisa Pedrana, Burnet Institute, Australia

---

24. Towards micro-elimination of hepatitis C in Skåne Region – The needle exchange programs as key assets.

Speaker: Marianne Alanko Blomé, Department Of Infectious Diseases, Skåne University Hospital, Malmö, Sweden, Sweden

---

25. Mobile Van Outreach for Primary Care and Hepatitis C Treatment for People Who Use Drugs in Victoria, British Columbia

Speaker: Tamara Barnett, Cool Aid Community Health Center, Canada

---

26. Working with People with Lived Experience of Hepatitis C: Point of Care Testing in Victoria, British Columbia

Speaker: Tamara Barnett, Cool Aid Community Health Center, Canada

---

28. Co-construction of prescribed safer supply knowledge, practices, and programs.

Speaker: Matt Bonn, Canadian Association of People Who Use Drugs (CAPUD), Canada

---

30. Point of care testing for hepatitis C infection in adult Correctional Centres in New South Wales, Australia

Speaker: Tracey Brown, Justice Health And Forensic Mental Health Network, Australia

---

31. Hepatitis B and C health promotion and prison to community follow up in South Western Uganda.

Speaker: Arafat Bwambale, GREAT LAKES PEACE CENTRE, Uganda

---

32. MANAS, a Peer-Led Project Among Women Using Drugs and Engaging in Sex Work

Speaker: Joana Canedo, EuroNPUD, Portugal

---

33. Tolerância Zero

Speaker: Paula Carriço, Cri Coimbra, Portugal

---

34. Integrated healthcare services for people who use drugs and alcohol followed at the HepC Virtual Clinic from Lausanne, Switzerland

Speaker: Erika Castro Batänjer, Cabinet de groupe Dr Castro et Dr Koffi-Blanchard, Suisse

---

35. A model of care to micro-eliminate hepatitis C in PWID managed at a low-threshold program in Slovenia.

Speaker: Jasna Černoša, Clinic For Infectious Diseases And Febrile Illnesses Ljubljana, Slovenia

---

37. Impact of an Innovative Community-Based Contracted Pharmacy on HCV Elimination in New Jersey, USA

Speaker: Corey DeStefano, North Jersey Community Research Initiative (njcri), United States

---

36. Understanding Hepatitis C Reinfection and Factors Associated with HCV Infection in New Jersey, USA.

Speaker: Corey DeStefano, North Jersey Community Research Initiative (njcri), United States

---

27. Safer supply enables life: Expanding the continuum of care for people who use drugs

Speaker: Matt Bonn, Canadian Association of People Who Use Drugs (CAPUD), Canada

---

38. In-person interactions impact on HCV, HIV, and Syphilis Rates in At Risk Populations

Speaker: Pam Ford, Omega Nurses/SRx Health Solutions, Canada

---

44. Community leadership delivering innovation in elimination: Australia’s National Hepatitis C Finding 50,000 Project

Speaker: Carrie Fowlie, Hepatitis Australia, Australia

---

45. CUPS Liver Clinic Conjoint Care Model to support connection to HCV care in Calgary, Alberta, Canada

Speaker: Nicola Gale, CUPS Liver Clinic, Canada

---

46. Parent-Child Assistance Program (PCAP).

Speaker: Sarah Gander, NB Social Pediatrics, Canada

---

47. Creating a community-led crisis response to support people who use drugs and who are in legal custody in Southern Highlands, Tanzania.

Speaker: Janeth Godfrey Godfrey, Serve Tanzania ( SETA), Tanzania, United Republic of

---

48. Supplementing hard to reach health services in Oslo – A mobile outreach model.

Speaker: Maria Helseth Greve, Foundation of Franciscan Aid, Nurses On Wheels, Norge

---

49. French remote support services for chemsexers – A polyvalent tool to harm reduction.

Speaker: Kaj Hamelin, Aides, France

---

52. Inclusion (part of Midlands Partnership Foundation Trust) Hepatitis C (HCV) elimination.

Speaker: Louise Hansford, Hep C U Later (Inclusion MPFT), UK

---

51. Tackling health inequalities.

Speaker: Louise Hansford, Hep C U Later (Inclusion MPFT), UK

---

50. Utilizing the patient search tool to find people with untreated hepatitis C in primary care.

Speaker: Louise Hansford, Hep C U Later (Inclusion MPFT), UK

---

54. Participant satisfaction among those enrolled in the Kentucky Viral Hepatitis Treatment (KeY TREAT) study achieving SVR.

Speaker: Jennifer Havens, University Of Kentucky College Of Medicine, United States

---

53. Predictors of loss to follow-up (LTFU) among rural residents enrolled in the Kentucky Viral Hepatitis Treatment (KEY TREAT) trial in Appalachian Kentucky.

Speaker: Jennifer Havens, University Of Kentucky College Of Medicine, United States

---

55. Life after Hepatitis C – An Education Package

Speaker: Gail Hawthorne, Castle Street Clinic, Ireland

---

56. Maintaining HCV Micro elimination through tines of Crisis: Ukrainian Refugees and People seeking international protection

Speaker: Gail Hawthorne, Castle Street Clinic, Ireland

---

58. Hepatitis C Testing and Treatment services through a One –Stop Model service delivery for People who Inject Drugs (PWID) in urban Colombo, Sri Lanka

Speaker: Sathya Herath, National STD/AIDS Control Program, Sri Lanka

---

57. Peer to Peer networking in Identifying Hepatitis C infections among people who inject drugs (PWID) in an urban city, Sri Lanka.

Speaker: Sathya Herath, National STD/AIDS Control Program, Sri Lanka

---

15. Female sexual and reproductive health clinic in an addiction clinic- can it be done?

Speaker: Lina Hijazi, Arud, Center for Addiction Medicine, Switzerland

---

59. UNODC’s Efforts to Improve the Health of the Most Forgotten Citizens in Myanmar – The Development of Standard Operating Procedures on Health Care in Prisons

Speaker: KO KO HLAING, United Nations Office On Drugs And Crime (UNODC), Myanmar, Myanmar

---

60. Reasons for a high drop-out of opioid agonist therapy (OAT) among clients in Mbeya, Tanzania.

Speaker: Damali Lucas Kabwali, Henry Jackson Foundation, Medical Research International ( Hjfmri Tanzania), Tanzania

---

62. Harm Reduction and Recovery in the UK: lessons learnt, hope for the future.

Speaker: Tracey Kemp, Change Grow Live, United Kingdom

---

61. Paving the Way for the Future: An Integrated Approach to Hepatitis C Elimination and Its Longevity.

Speaker: Tracey Kemp, Change Grow Live, United Kingdom

---

64. Sustaining the elimination of hepatitis C among people who continue to inject drugs.

Speaker: Tracey Kemp, Change Grow Live, United Kingdom

---

63. The Sustainability of Micro Elimination of Hepatitis C – Sustaining Safety! Adapting Provision to Mitigate Adversity.

Speaker: Tracey Kemp, Change Grow Live, United Kingdom

---

65. Environments of shelter for womxn who use drugs.

Speaker: Lexuri Ledesma, Metzineres, Spain

---

67. Programme to eliminate hepatitis C in a network of 49 prisons through multi-stakeholder partnership.

Speaker: Arran Ludlow-rhodes, Gilead Sciences, United Kingdom

---

68. Screening and Treatment of Hepatitis C in Cork Prison

Speaker: Conor McGarry, Portlaoise Prison, Ireland

---

69. MPACT: Methadone Patient Access to Collaborative Treatment.

Speaker: Beth Meyerson, University Of Arizona College of Medicine, Harm Reducton Research Lab, United States

---

70. Choice of HCV testing pathway in prisons is not a barrier to freedom from HCV.

Speaker: Louise Missen, Gilead Sciences, United Kingdom

---

91. Overdose safety helpline during the COVID-19 pandemic – A promising new service & lessons learned.

Speaker: Stephen Murray, Boston Medical Center, United States

---

72. Community prevention against organized crime.

Speaker: Kennedy Mutale, Decisive Minds, Zambia

---

73. Incidence of hepatitis C virus co-morbidities among people who inject drugs in Mombasa County, Kenya.

Speaker: Mohammed Mwakazi, County Government Of Mombasa, Kenya, Kenya

---

74. Community screening during ISW (International Screening Week) among drug users in Burundi

Speaker: Armand Nsababaganwa, Bapud, Burundi

---

75. HCV treatment uptake following point-of-care HCV testing at a mobile community clinic in Queensland, Australia: The Kombi Clinic

Speaker: Joss O’Loan, Kombi Clinic, Australia

---

76. Outreach and engagement to achieve hepatitis C micro-elimination in Cairns, Australia.

Speaker: Alisa Pedrana, Burnet Institute, Australia

---

78. A comprehensive approach to homeless people with addictions in an emergency shelter in Lisbon.

Speaker: Claudia Pereira, Ares Do Pinhal, Portugal

---

79. New approaches to HCV diagnosis and treatment initiation in a mobile outreach program in Lisbon.

Speaker: Claudia Pereira, Ares Do Pinhal, Portugal

---

80. Reducing and working around unnecessary barriers to treatment in an overwhelmed healthcare system: Nurse-led hepatitis C (HCV) testing, rapid treatment, and retention in an Atlantic Canadian harm reduction iOAT drug treatment program.

Speaker: Michelle Pittman, River Stone Recovery Centre, Canada

---

81. Screening hepatitis C in harm reduction centers in France, before, during and after Covid, what’s the impact of the crisis?

Speaker: Juliette Pont, SOS Hépatites Bourgogne Franche-Comté, France

---

82. arpa-chemsex project (enhanced multidisciplinary network support-chemsex project in France).

Speaker: Jonathan Rayneau, Federation Addiction, France

---

84. A repeat, high-intensity, peer-led testing intervention in community pharmacy

Speaker: Leila Reid, The Hepatitis C Trust, United Kingdom

---

83. Peer-led, point of care RNA testing for people experiencing homelessness

Speaker: Leila Reid, The Hepatitis C Trust, United Kingdom

---

85. Integrating viral hepatitis services for people who use drugs into inpatient substance use treatment programs via telehealth.

Speaker: Farah Riazi, The REACH Program at Mount Sinai Hospital, United States

---

41. A Mothers Arms: Sanctum 1.5; A novel approach to treating substance misuse in pregnant woman and preventing infant apprehension at birth.

Speaker: Katelyn Roberts& Morris Markentin, Sanctum Care Group Inc., Canada & Morris Markentin, Sanctum Care Group, Canadat

---

86. Where are WE! Rhetoric Voice of the People Who Use Drugs [PWUD] in Kenya as we Seek a Voice from a Void of Harm Reduction:

Speaker: Ahmed Mohamed Said, Kwale Network of People Who Use Drugs, Kenya

---

87. Who can see us! Overlapping risks of men who have sex with men [MSM] and sex work among PWUD in Kwale County, Kenya.

Speaker: Ahmed Mohamed Said, Kwale Network of People Who Use Drugs, Kenya

---

88. Simplified hepatitis C testing and linkage to care in addiction recovery and community correctional facilities model of care

Speaker: Kathi Scholz, Central Outreach Wellness Center, United States

---

90. Increasing HCV testing and treatment uptake among women in the criminal justice system: A specialist peer-led model

Speaker: Julia Sheehan, The Hepatitis C Trust, United Kingdom

---

92. A mobile van-based clinic offers improved access to hepatitis C assessment with high treatment initiation rates in historically untreated people living with hepatitis C

Speaker: Ben Stone, Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom

---

93. Factors Associated with Implementation of Innovative Models of HCV Care and Treatment in New York State for People Who Inject Drugs

Speaker: Isabella Sunkes, School of Public Health, University At Albany, United States

---

94. The participation of Peer educators who use injection drugs in HIV, HCV and harm reduction services in Cameroon (case of ALCONDOMS Cameroon).

Speaker: Moise Wadjo Noupa, Alcondoms Cameroon, Cameroon

---

95. ARUD PEER PROJECT

Speaker: Oliver Wehrli, Arud Centre For Addiction Medicine, Schweiz

---

96. Implementation of blood borne virus testing in a forensic psychiatric unit

Speaker: Kate Williams, Oxleas NHS Foundation Trust, United Kingdom

---

97. Sofosbuvir/velpatasvir (S/V) for the treatment of hepatitis C virus (HCV) infection among vulnerable inner-city residents: Extending the results of clinical trial part 2.

Speaker: Rossitta Yung, Vancouver Infectious Diseases Centre, Canada

---

98. Barriers to accessing hepatitis C treatment among people who inject drugs.

Speaker: Mojgan Zare, Georgia Harm Reduction Coalition, United States

---

2. ‘I can change my life’: Perceptions and experiences of people who use drugs engaging in MAT in Kiambu County, Kenya.

Speaker: Doris Burtscher, Médecins Sans Frontières, Austria

---

163. What makes the difference? Self-identified goal setting by birthing people who use substances (BPWUS) in the Parent Child Assistance Program.

Speaker: Sarah Campbell, Horizon Health Network, Canada

---

3. Measuring opioid agonist treatment stigma and its effects: An exploration of pharmacist attitudes and consumer treatment outcomes.

Speaker: Theresa Caruana, University Of New South Wales – Centre For Social Research In Health, Australia

---

16. Barriers and enablers to point-of-care HCV testing: A qualitative study using the Theoretical Domains Framework comparing the perspectives of Needle and Syringe Program workers and people who inject drugs.

Speaker: Guillaume Fontaine, McGill University, Canada

---

5. Tailoring Harm Reduction Services to the Needs of Young People Who Use Drugs.

Speaker: Brendan Kahn, The University of Vienna, Austria

---

6. Reimbursing incarcerated individuals for participation in research: A scoping review.

Speaker: Nadine Kronfli, Mcgill University, Canada

---

7. An analysis of punitive income support policies and the impacts on birthing parents who use substances.

Speaker: Sarah Lunney, Horizon Health Network, Canada

---

8. Lost in translation: U.S. federal policy changes did not result in sustained methadone treatment changes during COVID, Arizona.

Speaker: Beth Meyerson, University Of Arizona College of Medicine, Harm Reducton Research Lab, United States

---

9. Briefing paper: Gender-based violence against women and people of diverse gender identity and expression who use drugs: Integrating practical responses into harm reduction and HIV prevention and treatment.

Speaker: Iryna Mikhnovets, UNODC, Austria

---

10. Who will end the drug war? A white paper on the role of relevant stakeholders in Nigeria.

Speaker: Isaac Ogunkola, Youth RISE International, Nigeria

---

11. Health Un/Care: Missed Opportunities in Pharmacy Interactions with PWID Seeking Sterile Syringes

Speaker: Danielle Russell, Arizona State University, United States

---

12. National Prisons Hepatitis Network: National consensus statement on the management of hepatitis C in Australia’s prisons.

Speaker: Yumi Sheehan, The Kirby Institute, UNSW SYDNEY, Australia

---

13. Identifying and understanding the needs for hepatitis C (HCV) education to enhance HCV health literacy and HCV care for people in Australian prisons.

Speaker: Yumi Sheehan, The Kirby Institute, UNSW SYDNEY, Australia

---

14. Assessing Faith-Based Stigma and Discrimination Against People Who Use Drugs in Indonesia.

Speaker: Kiki Marini Situmorang, Community Legal Aid Institute (LBH Masyarakat), Indonesia

---

20. HIV outcomes 12 months after release: Evaluating the impact of two Louisiana pre-release interventions.

Speaker: Olivia Sugarman, Johns Hopkins Bloomberg School Of Public Health, United States

---

21. Australian police custody and people who use drugs: Gaps and opportunities

Speaker: Shelley Walker, National Drug Research Institute, Australia

---